Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
A randomized non-inferior trial comparing remimazolam besylate with propofol for long-term sedation during invasive mechanical ventilation in critically ill patients
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Remimazolam besylate | Experimental | Remimazolam besylate at an initial infusion rate of 0.15 mg/kg/h and adjusted (maximum of 0.3 mg/kg/h) to maintain a RASS score between - 3 and 0 |
|
| Propofol | Active Comparator | Propofol intravenously at an initial infusion rate of 2.0 mg/kg/h and adjusted (maximum of 4.0 mg/kg/h) to maintain a RASS score between - 3 and 0 |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Remimazolam besylate | Drug | Sedation drug |
| |
| Propofol |
| Measure | Description | Time Frame |
|---|---|---|
| The percentage of time in the target sedation range without rescue sedation | The percentage of time in the target sedation range without rescue sedation | 7 days after enrollment, or when patients decease, require deep sedation, are scheduled for surgery, are discontinued from the study drug for at least 12 hours, are discharged from ICU, or are withdrawn from the trial, whichever comes first |
| Measure | Description | Time Frame |
|---|---|---|
| Invasive ventilator free time | Hours of time free from invasive ventilator | From start of study to 7 days |
| Successful extubation rate | Extubation of endotracheal tube for the first time in 7 days without reintubation or switching to tracheostomy within the following 48 hours |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| You Shang, MD | Contact | 008602785726114 | 61606 | you_shanghust@163.com |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Department of Critical Care Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Recruiting | Wuhan | China |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 37576823 | Derived | Yang X, Tang Y, Du R, Yu Y, Xu J, Zhang J, Liu H, Zou X, Ren L, Yuan S, Shang Y. Long-term sedation with remimazolam besylate versus propofol in critically ill patients during invasive mechanical ventilation: a study protocol for a multicenter randomized non-inferior trial. Front Pharmacol. 2023 Jul 28;14:1139872. doi: 10.3389/fphar.2023.1139872. eCollection 2023. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D015742 | Propofol |
| ID | Term |
|---|---|
| D010636 | Phenols |
| D001555 | Benzene Derivatives |
| D006841 | Hydrocarbons, Aromatic |
| D006844 | Hydrocarbons, Cyclic |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Drug |
Propofol. Sedation drug |
|
| From start of study to 7 days |
| Length of ICU stay | Length of ICU stay | From start of study to 28 days |
| Mortality | Mortality | From start of study to 28 days |
| Length of hospitalization | Length of hospitalization | From start of study to 28 days |
| weaning time | weaning time in minutes between continuous discontinuation of the study drug and extubation in patients with successful extubation | From start of study to 7 days |
| Rate of hypotension | Systolic blood pressure less than 80 mmHg or diastolic blood pressure less than 50 mmHg for 5 minutes or treated with vasopressors | 7 days after enrollment, or when patients decease, require deep sedation, are scheduled for surgery, are discontinued from the study drug for at least 12 hours, are discharged from ICU, or are withdrawn from the trial, whichever comes first |
| Rate of hypertension | systolic blood pressure greater than 160 mm Hg or diastolic blood pressure greater than 100 mmHg for 5 minutes or treated with vasodilators | 7 days after enrollment, or when patients decease, require deep sedation, are scheduled for surgery, are discontinued from the study drug for at least 12 hours, are discharged from ICU, or are withdrawn from the trial, whichever comes first |
| Rate of bradycardia | heart rate less than 50 bpm for 5 minutes or treated with medication to increase heart rate | 7 days after enrollment, or when patients decease, require deep sedation, are scheduled for surgery, are discontinued from the study drug for at least 12 hours, are discharged from ICU, or are withdrawn from the trial, whichever comes first |
| Rate of tachycardia | heart rate greater than 120 bpm for 5 minutes or treated with medication to decrease heart rate | 7 days after enrollment, or when patients decease, require deep sedation, are scheduled for surgery, are discontinued from the study drug for at least 12 hours, are discharged from ICU, or are withdrawn from the trial, whichever comes first |
| Rate of unplanned extubation of endotracheal tube | unplanned extubation of endotracheal tube | 7 days after enrollment, or when patients decease, require deep sedation, are scheduled for surgery, are discontinued from the study drug for at least 12 hours, are discharged from ICU, or are withdrawn from the trial, whichever comes first |
| Rate of shock | New-onset shock | 7 days after enrollment, or when patients decease, require deep sedation, are scheduled for surgery, are discontinued from the study drug for at least 12 hours, are discharged from ICU, or are withdrawn from the trial, whichever comes first |
| Rate of hospital-acquired pneumonia | hospital-acquired pneumonia | 7 days after enrollment, or when patients decease, require deep sedation, are scheduled for surgery, are discontinued from the study drug for at least 12 hours, are discharged from ICU, or are withdrawn from the trial, whichever comes first |
| Rate of myocardial infarction | myocardial infarction | 7 days after enrollment, or when patients decease, require deep sedation, are scheduled for surgery, are discontinued from the study drug for at least 12 hours, are discharged from ICU, or are withdrawn from the trial, whichever comes first |
| Rate of cerebral ischemic stroke | cerebral ischemic stroke | 7 days after enrollment, or when patients decease, require deep sedation, are scheduled for surgery, are discontinued from the study drug for at least 12 hours, are discharged from ICU, or are withdrawn from the trial, whichever comes first |
| Rate of cerebral hemorrhagic stroke | Rate of cerebral hemorrhagic stroke | 7 days after enrollment, or when patients decease, require deep sedation, are scheduled for surgery, are discontinued from the study drug for at least 12 hours, are discharged from ICU, or are withdrawn from the trial, whichever comes first |
| Rate of pulmonary embolism | pulmonary embolism | 7 days after enrollment, or when patients decease, require deep sedation, are scheduled for surgery, are discontinued from the study drug for at least 12 hours, are discharged from ICU, or are withdrawn from the trial, whichever comes first |
| Rate of upper digestive tract ulcer confirmed endoscopically | upper digestive tract ulcer confirmed endoscopically | 7 days after enrollment, or when patients decease, require deep sedation, are scheduled for surgery, are discontinued from the study drug for at least 12 hours, are discharged from ICU, or are withdrawn from the trial, whichever comes first |
| Rate of more than 500 milliliters of bloody stool | more than 500 milliliters of bloody stool | 7 days after enrollment, or when patients decease, require deep sedation, are scheduled for surgery, are discontinued from the study drug for at least 12 hours, are discharged from ICU, or are withdrawn from the trial, whichever comes first |
| Rate of delirium | delirium | 7 days after enrollment, or when patients decease, require deep sedation, are scheduled for surgery, are discontinued from the study drug for at least 12 hours, are discharged from ICU, or are withdrawn from the trial, whichever comes first |
| delta SOFA | defined as the difference between SOFA when each patient stops receiving the study drug and SOFA at inclusion | 7 days after enrollment, or when patients decease, require deep sedation, are scheduled for surgery, are discontinued from the study drug for at least 12 hours, are discharged from ICU, or are withdrawn from the trial, whichever comes first |
| Rate of withdraw from the trial because of intolerance, severe adverse events or other safety concerns | rate of withdraw from the trial because of intolerance, severe adverse events or other safety concerns | 7 days after enrollment, or when patients decease, require deep sedation, are scheduled for surgery, are discontinued from the study drug for at least 12 hours, are discharged from ICU, or are withdrawn from the trial, whichever comes first |
| D006838 |
| Hydrocarbons |
| D009930 | Organic Chemicals |